Chloramphenicol Inj Rx
Generic Name and Formulations:
Chloramphenicol sodium succinate 100mg/mL; pwd for IV inj after reconstitution; sodium content 2.25 mEq/g chloramphenicol; preservative-free.
Various generic manufacturers
Indications for Chloramphenicol Inj:
Serious susceptible infections resistant to other antibiotics. Typhoid fever. Cystic fibrosis regimens.
Give by IV inj over ≥1-minute interval. 50mg/kg per day in 4 divided doses every 6 hours. Moderately resistant infections: may increase up to 100mg/kg per day, reduce dose as soon as possible. Typhoid fever: give for 8–10 days after patient has become afebrile. Renal or hepatic impairment: adjust or reduce dose. Switch to oral form as soon as possible.
Give by IV inj over ≥1-minute interval. Premature, full-term infants <2 weeks old, or children with immature metabolic processes: 25mg/kg per day in 4 divided doses every 6 hours. Children >2 weeks old: up to 50mg/kg per day in 4 divided doses every 6 hours. Severe infections (eg, bacteremia, meningitis): up to 100mg/kg per day, reduce to 50mg/kg per day as soon as possible. Typhoid fever: give for 8–10 days after patient has become afebrile. Switch to oral form as soon as possible.
Not for trivial infections or prophylaxis. Previous toxic reactions to chloramphenicol.
Renal or hepatic impairment. Obtain baseline CBCs then every 2 days during therapy; discontinue if blood dyscrasias, optic neuritis or peripheral neuritis develops. Avoid repeat therapy. Monitor serum levels. Premature and newborn infants. Labor & delivery. Pregnancy. Nursing mothers.
Avoid other bone marrow suppressants.
Serious/fatal blood dyscrasias, paroxysmal nocturnal hemoglobinemia, GI upset, headache, confusion, delirium, optic and peripheral neuritis, gray baby syndrome, rashes, anaphylaxis, Herxheimer reactions (w. typhoid fever).
Formerly known under the brand names Chlormycetin, Mychel S.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC